Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Community-acquired pneumonia: the evolving challenge.

R Finch1

  • 1Division of Microbiology and Infectious Diseases, The City Hospital, Nottingham, UK.

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|August 29, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

European quality clearance of new microbiological diagnostics.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2012
Same author

Healthcare workers and influenza vaccination: an ERS-ESCMID Web-based survey.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2011
Same author

Ectonucleoside triphosphate diphosphohydrolase type 5 (Entpd5)-deficient mice develop progressive hepatopathy, hepatocellular tumors, and spermatogenic arrest.

Veterinary pathology·2009
Same author

Tigecycline: in-vitro performance as a predictor of clinical efficacy.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2007
Same author

Prognostic influence of multiple hepatic metastases from colorectal cancer.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2006
Same journal

How stable are antimicrobial susceptibility profiles in serial clinical isolates? A retrospective study informing repeat-testing strategies.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Impact of low-dose chest CT and multiplex PCR on antibiotic usage for community-acquired pneumonia: multicentre prospective controlled before-after study with cluster randomisation (CAP-NEXT study).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Clinical Microbiology and Infection: how did we do in 2025?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Automate the work, not the decision: aligning expectations for AI in clinical microbiology.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Doxycycline prophylaxis and gonococcal resistance: reassurance, residual signals, and the case for surveillance.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Oral metronidazole versus clindamycin to treat bacterial vaginosis in pregnancies at risk for preterm labor.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
See all related articles

Community-acquired pneumonia (CAP) treatment is evolving with new evidence-based guidelines. Telithromycin, a novel ketolide antibiotic, shows over 90% efficacy in treating CAP, even against resistant pathogens.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Community-acquired pneumonia (CAP) is a significant global health concern with complex microbial causes.
  • Current CAP management often relies on empirical therapy and guidelines based on expert opinion rather than strong evidence.
  • Assessing CAP severity and understanding local pathogen resistance patterns are crucial for effective treatment strategies.

Purpose of the Study:

  • To review the evolving landscape of CAP management, focusing on new evidence-based guidelines.
  • To evaluate the efficacy of novel antimicrobial agents, particularly ketolides, in CAP treatment.
  • To highlight telithromycin's effectiveness against resistant pathogens in CAP.

Main Methods:

  • Review of international research on CAP epidemiology, etiology, and management.

Related Experiment Videos

  • Analysis of newly developed evidence-based clinical guidelines for CAP.
  • Evaluation of clinical trial data for telithromycin in CAP treatment.

    • Main Results:

    • New guidelines incorporate disease severity, local pathogen resistance, and newer antimicrobials like macrolides and fluoroquinolones.
    • Telithromycin, a ketolide, demonstrated clinical and bacteriological success rates exceeding 90% in over 700 CAP patients.
    • Telithromycin maintained efficacy against resistant pathogens, offering an advantage over existing therapies.

    Conclusions:

    • Evidence-based guidelines are improving CAP management by considering disease severity and local resistance.
    • Telithromycin represents a promising new therapeutic option for CAP, offering high efficacy and activity against resistant strains.
    • The development of novel agents like ketolides is essential to combat antimicrobial resistance in CAP treatment.